{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:03:43Z","timestamp":1788188623581,"version":"build-2803163510"},"reference-count":34,"publisher":"Informa UK Limited","issue":"1-2","license":[{"start":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Hexal AG, Holzkirchen, Germany"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1080\/14712598.2024.2308645","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T10:40:04Z","timestamp":1706179204000},"page":"91-100","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males"],"prefix":"10.1080","volume":"24","author":[{"given":"Barbara","family":"Vogg","sequence":"first","affiliation":[{"name":"Clinical Development Biopharmaceuticals, Hexal AG, Holzkirchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Poetzl","sequence":"additional","affiliation":[{"name":"Clinical Development Biopharmaceuticals, Hexal AG, Holzkirchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"El Galta","sequence":"additional","affiliation":[{"name":"Clinical Development Biopharmaceuticals, Hexal AG, Holzkirchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainard","family":"Fuhr","sequence":"additional","affiliation":[{"name":"Principal Investigator Early Phase Clinical Unit, Parexel International GmbH, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnd","family":"Schwebig","sequence":"additional","affiliation":[{"name":"Clinical Development Biopharmaceuticals, Hexal AG, Holzkirchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susmit","family":"Sekhar","sequence":"additional","affiliation":[{"name":"Clinical Development Biopharmaceuticals, Hexal AG, Holzkirchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,1,26]]},"reference":[{"key":"e_1_3_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155559"},{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00325"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.251"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2017.00234"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1063815"},{"key":"e_1_3_7_7_1","unstructured":"EMA. Prolia EU SmPC [Internet]. 2020 [cited 2023 Aug 8]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/prolia-epar-product-information_en.pdf"},{"key":"e_1_3_7_8_1","unstructured":"FDA. Xgeva (denosumab) [US package insert]. 2022. [cited 2023 Dec 2]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125320s094lbl.pdf"},{"key":"e_1_3_7_9_1","unstructured":"EMA. Xgeva EU SmPC [Internet]. 2016 [cited 2023 Aug 8]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xgeva-epar-product-information_en.pdf"},{"key":"e_1_3_7_10_1","unstructured":"FDA. Prolia (denosumab) [US package insert]. Prolia (denosumab) [package insert]. 2023. [cited 2023 Dec 2]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125320s205lbl.pdf"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-016-0060-5"},{"key":"e_1_3_7_12_1","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products [Internet]. 2014 [cited 2023 Sep 13]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-rev1_en.pdf"},{"key":"e_1_3_7_13_1","unstructured":"U.S. Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance For Industry [Internet]. 2015 [cited 2023 Sep 13]. Available from: https:\/\/www.fda.gov\/media\/82647\/download."},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14122721"},{"key":"e_1_3_7_15_1","first-page":"OCT4","volume-title":"World congress on osteoporosis, osteoarthritis, and musculoskeletal diseases","author":"Jeka S","year":"2023","unstructured":"Jeka S, Dokoupilov\u00e1 E, Kivitz A, et al. Efficacy and safety of proposed denosumab biosimilar and reference denosumab in postmenopausal osteoporosis at 52 weeks: the ROSALIA study. In World congress on osteoporosis, osteoarthritis, and musculoskeletal diseases. Barcelona Spain: The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases; The International Osteoporosis Foundation; 2023. p. OCT4."},{"key":"e_1_3_7_16_1","first-page":"P303","volume-title":"World congress on osteoporosis, osteoarthritis, and musculoskeletal diseases","author":"Jeka S","year":"2023","unstructured":"Jeka S, Dokoupilov\u00e1 E, Kivitz A, et al. Pharmacokinetics and pharmacodynamics of proposed denosumab biosimilar and reference denosumab in postmenopausal osteoporosis: the ROSALIA study. In World congress on osteoporosis, osteoarthritis, and musculoskeletal diseases. Barcelona Spain: The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases; The International Osteoporosis Foundation; 2023. p. P303."},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.2165\/11594240-000000000-00000"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-015-9422-4"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-011-1786-8"},{"key":"e_1_3_7_20_1","unstructured":"FDA. Bioanalytical method validation. Guidance for industry. 2018 [Internet]. [cited 2024 Jan 11]. Available from: https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf"},{"key":"e_1_3_7_21_1","unstructured":"EMA. Guideline on bioanalytical method validation. 2012 [Internet]. [cited 2024 Jan 11]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf"},{"key":"e_1_3_7_22_1","unstructured":"EMA. ICH guideline M10 on bioanalytical method validation. 2023 [Internet]. [cited 2024 Jan 11]. Available from: https:\/\/www.ema.europa.eu\/en\/ich-m10-bioanalytical-method-validation-scientific-guideline"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01068419"},{"key":"e_1_3_7_24_1","unstructured":"Amgen Inc. Xgeva US PI [Internet]. 2020 [cited 2023 Aug 8]. Available from: https:\/\/www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-com\/Xgeva\/xgeva_pi.pdf"},{"key":"e_1_3_7_25_1","volume-title":"Immunogenicity information in human prescription therapeutic protein and select drug product labeling \u2014 content and format guidance for industry","author":"FDA","unstructured":"FDA. Immunogenicity information in human prescription therapeutic protein and select drug product labeling \u2014 content and format guidance for industry."},{"key":"e_1_3_7_26_1","article-title":"Immunogenicity testing of therapeutic protein products \u2014 developing and validating assays for anti-drug antibody detection","author":"FDA","year":"2019","unstructured":"FDA. Immunogenicity testing of therapeutic protein products \u2014 developing and validating assays for anti-drug antibody detection. Guidance For Industry. 2019.","journal-title":"Guidance For Industry"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200948030-00001"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12362"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-017-4082-4"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2013.09.010"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-601"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-020-01153-7"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108666"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2022.2123737"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-1584"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2024.2308645","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T12:54:39Z","timestamp":1727268879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2024.2308645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,26]]},"references-count":34,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1080\/14712598.2024.2308645"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2024.2308645","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-12-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}